Processa Pharmaceuticals, Inc. (PCSA)

NASDAQ: PCSA · IEX Real-Time Price · USD
1.760
-0.080 (-4.35%)
At close: May 23, 2024, 12:00 AM
2.010
+0.250 (14.20%)
Pre-market: May 24, 2024, 8:57 AM EDT
-4.35%
Market Cap 5.03M
Revenue (ttm) n/a
Net Income (ttm) -9.83M
Shares Out 2.86M
EPS (ttm) -6.39
PE Ratio n/a
Forward PE n/a
Dividend n/a
Ex-Dividend Date n/a
Volume 1,509
Open 1.820
Previous Close 1.840
Day's Range 1.740 - 1.860
52-Week Range 1.400 - 18.000
Beta 0.53
Analysts Buy
Price Target 6.00 (+240.91%)
Earnings Date May 10, 2024

About PCSA

Processa Pharmaceuticals, Inc., a clinical stage biopharmaceutical company, develops chemotherapy drugs to improve the safety and efficacy of cancer treatment. Its drugs are modifications of existing FDA-approved oncology drugs resulting in an alteration of the metabolism and/or distribution of drugs while maintaining the existing mechanisms of killing the cancer cells. The company's pipeline includes three chemotherapy drugs comprising Gemcitabine, PCS3117 that has completed Phase 2a clinical trials to treat pancreatic, biliary tract, lung, ov... [Read more]

Industry Biotechnology
Sector Healthcare
Founded 2011
Employees 13
Stock Exchange NASDAQ
Ticker Symbol PCSA
Full Company Profile

Financial Performance

Financial Statements

Analyst Forecast

According to 3 analysts, the average rating for PCSA stock is "Buy." The 12-month stock price forecast is $6.0, which is an increase of 240.91% from the latest price.

Price Target
$6.0
(240.91% upside)
Analyst Consensus: Buy
Stock Forecasts

News

Processa Pharmaceuticals to Participate in the EF Hutton Annual Global Conference

HANOVER, Md., May 06, 2024 (GLOBE NEWSWIRE) -- Processa Pharmaceuticals, Inc. (Nasdaq: PCSA) (“Processa” or the “Company”), a clinical-stage pharmaceutical company focused on developing the next gener...

18 days ago - GlobeNewsWire

Processa Pharmaceuticals Names Dr. Steven Cha Senior Vice President of Clinical Research

Brings extensive experience in all phases of oncology drug development HANOVER, Md., April 30, 2024 (GLOBE NEWSWIRE) -- Processa Pharmaceuticals, Inc. (Nasdaq: PCSA) (Processa or the Company), a clini...

24 days ago - GlobeNewsWire

Processa Pharmaceuticals to Present at the MedInvest Biotech and Pharma Investor Conference

HANOVER, MD, March 28, 2024 (GLOBE NEWSWIRE) -- Processa Pharmaceuticals, Inc. (Nasdaq: PCSA) (“Processa” or the “Company”), a clinical-stage pharmaceutical company focused on developing the next gene...

2 months ago - GlobeNewsWire

Processa Pharmaceuticals to Present Data at the American Association for Cancer Research Annual Meeting

HANOVER, MD, March 25, 2024 (GLOBE NEWSWIRE) -- Processa Pharmaceuticals, Inc. (Nasdaq: PCSA) (“Processa” or the “Company”), a clinical-stage pharmaceutical company focused on developing the next gene...

2 months ago - GlobeNewsWire

Processa Pharmaceuticals to Present at the 2024 BIO CEO & Investor Conference

HANOVER, MD, Feb. 21, 2024 (GLOBE NEWSWIRE) -- Processa Pharmaceuticals, Inc. (Nasdaq: PCSA) (“Processa” or the “Company”), a clinical-stage pharmaceutical company focused on developing the next gener...

3 months ago - GlobeNewsWire

Processa Pharmaceuticals to Present at The Winter Wrap-Up MicroCap Rodeo Winter 2024 Virtual Conference

HANOVER, MD, Feb. 14, 2024 (GLOBE NEWSWIRE) -- Processa Pharmaceuticals, Inc. (Nasdaq: PCSA) (“Processa” or the “Company”), a clinical-stage pharmaceutical company focused on developing the next gener...

3 months ago - GlobeNewsWire

Processa Pharmaceuticals Regains Compliance with Nasdaq Minimum Bid Price Rule

HANOVER, MD, Feb. 06, 2024 (GLOBE NEWSWIRE) -- Processa Pharmaceuticals, Inc. (Nasdaq: PCSA) (“Processa” or the “Company”), a clinical-stage pharmaceutical company focused on developing the next gener...

3 months ago - GlobeNewsWire

Processa Pharmaceuticals Announces Closing of $7.0 Million Public Offering

HANOVER, MD, Feb. 01, 2024 (GLOBE NEWSWIRE) -- Processa Pharmaceuticals, Inc. (Nasdaq: PCSA) (“Processa” or the “Company”), a clinical-stage pharmaceutical company focused on developing the next gener...

4 months ago - GlobeNewsWire

Processa Pharmaceuticals Announces Pricing of $7.0 Million Public Offering

HANOVER, Md., Jan. 26, 2024 (GLOBE NEWSWIRE) -- Processa Pharmaceuticals, Inc. (Nasdaq: PCSA) (“Processa” or the “Company”), a clinical-stage pharmaceutical company focused on developing the next gene...

4 months ago - GlobeNewsWire

What made Processa Pharmaceuticals stock nearly triple on Thursday?

Processa Pharmaceuticals Inc (NASDAQ: PCSA) says it has completed a safety evaluation of its cancer treatment. Its shares rallied well over 150% on Thursday.

4 months ago - Invezz

Processa Pharmaceuticals Announces Successful Completion of Phase 1b Safety Evaluation of NGC-Cap in Patients with Advanced Cancer Resulting in Recommended Phase 2 Doses

Next Generation Capecitabine (NGC-Cap) provides patients with 2-10 times greater exposure to its 5-FU cancer treatment metabolite than capecitabine administration

4 months ago - GlobeNewsWire

Processa Pharmaceuticals Announces Expansion of NGC-Cap Program into Advanced or Metastatic Breast Cancer

FDA and Processa agree to expand NGC-Cap development into breast cancer providing a more efficient path to approval FDA agrees that existing data and studies can be used to support the Phase 2 breast ...

4 months ago - GlobeNewsWire

Processa Pharmaceuticals to Effect a 1-for-20 Reverse Stock Split

HANOVER, MD, Jan. 18, 2024 (GLOBE NEWSWIRE) -- Processa Pharmaceuticals, Inc. (Nasdaq: PCSA) (“Processa” or the “Company”), a clinical-stage pharmaceutical company focused on developing the next gener...

4 months ago - GlobeNewsWire

Processa Pharmaceuticals to Present at the Biotech Showcase 2024

HANOVER, MD, Jan. 02, 2024 (GLOBE NEWSWIRE) -- Processa Pharmaceuticals, Inc. (Nasdaq: PCSA) (“Processa” or the “Company”), a clinical-stage pharmaceutical company focused on developing the next gener...

5 months ago - GlobeNewsWire

Processa Pharmaceuticals Provides Interim Analysis from Ongoing Phase 1b Trial of Next Generation Capecitabine Showing Improved Safety Over Capecitabine

FDA acknowledges that NGC-Cap is a New Chemical Entity given the changes to metabolism and distribution of its major metabolite 5-FU

5 months ago - GlobeNewsWire

Processa Pharmaceuticals Announces Successful Phase 2 Meeting with FDA for Next Generation Capecitabine

FDA provides guidance on Phase 2 design and Processa to continue with pre-study activities for Phase 2 trial

5 months ago - GlobeNewsWire

Processa Pharmaceuticals to Present at the MedInvest Oncology Investor Conference

HANOVER, MD, Nov. 30, 2023 (GLOBE NEWSWIRE) -- Processa Pharmaceuticals, Inc. (Nasdaq: PCSA) (“Processa” or the “Company”), a clinical-stage pharmaceutical company focused on developing the next gener...

6 months ago - GlobeNewsWire

Processa Pharmaceuticals Issues Letter to Shareholders Highlighting Corporate Strategy, Drug Pipeline, and Outlook

HANOVER, MD, Nov. 29, 2023 (GLOBE NEWSWIRE) -- Processa Pharmaceuticals, Inc. (Nasdaq: PCSA) (“Processa” or the “Company”), a clinical-stage pharmaceutical company now focused on developing the next g...

6 months ago - GlobeNewsWire

Processa Pharmaceuticals, Inc. Mourns the Sudden Passing of Board Member Virgil Thompson

Hanover, MD., Nov. 13, 2023 (GLOBE NEWSWIRE) -- Processa Pharmaceuticals, Inc. (Nasdaq: PCSA) announced today with great sadness that Virgil Thompson, Director, passed away unexpectedly on November 9,...

6 months ago - GlobeNewsWire

Processa Pharmaceuticals to Present at the 20th Orphan Drugs and Rare Diseases Global Congress 2023 Americas

HANOVER, MD, Nov. 09, 2023 (GLOBE NEWSWIRE) -- Processa Pharmaceuticals, Inc. (Nasdaq: PCSA) (“Processa” or the “Company”), a clinical-stage pharmaceutical company focused on developing the next gener...

7 months ago - GlobeNewsWire

Processa Pharmaceuticals Announces Formation of Oncology Advisory Board with Renowned Key Opinion Leaders

Company To Leverage World-Class Oncology Advisory Board in the Design of Oncology Trial Protocols, Including the Anticipated Phase 2 Trial for NGC-Cap

7 months ago - GlobeNewsWire

Processa Pharmaceuticals to Present at the ThinkEquity Conference

HANOVER, MD, Oct. 13, 2023 (GLOBE NEWSWIRE) -- Processa Pharmaceuticals, Inc. (Nasdaq: PCSA) (“Processa” or the “Company”), a clinical-stage pharmaceutical company focused on developing the next gener...

7 months ago - GlobeNewsWire

Processa Pharmaceuticals to Present at the H.C. Wainwright 25th Annual Global Investment Conference

HANOVER, MD, Sept. 06, 2023 (GLOBE NEWSWIRE) -- Processa Pharmaceuticals, Inc. (Nasdaq: PCSA) (“Processa” or the “Company”), a clinical-stage pharmaceutical company focused on developing the next gene...

9 months ago - GlobeNewsWire

Processa Pharmaceuticals Provides Data Update Supporting a Potential Personalized Treatment Approach for Improved Cancer Care

Interim analysis of Ph ase 1B data suggests Processa's novel chemotherapy treatment could improve safety and efficacy in more patients by individualizing the dosing regimen for each patient

10 months ago - GlobeNewsWire

Processa Pharmaceuticals to Present at the Sidoti & Co. Micro Cap Virtual Conference

HANOVER, MD, Aug. 10, 2023 (GLOBE NEWSWIRE) -- Processa Pharmaceuticals, Inc. (Nasdaq: PCSA) (“Processa” or the “Company”), a clinical-stage pharmaceutical company now focused on developing the next g...

10 months ago - GlobeNewsWire